Astrazeneca
Clinical trials sponsored by Astrazeneca, explained in plain language.
-
New hope for advanced breast cancer: two hormone therapies face off in major trial
Disease control CompletedThis study compared two hormone treatments for postmenopausal women with advanced breast cancer that responds to hormones. The trial involved 462 women who had not received prior hormone therapy. Researchers tested whether fulvestrant or anastrozole was more effective at delaying…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 04, 2026 00:21 UTC
-
New inhaler technology tested for COPD safety
Disease control CompletedThis study tested whether a new inhaler device (HFO) is as safe as a standard inhaler (HFA) when delivering the same triple-combination medication for COPD. It involved 559 adults with moderate to very severe COPD who used the inhalers twice daily for 12 weeks, with some continui…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 04, 2026 00:21 UTC
-
Targeted pill challenges chemo for inherited breast cancer
Disease control CompletedThis study tested whether a daily pill called olaparib could work better than standard chemotherapy for patients with advanced breast cancer who have specific inherited BRCA gene mutations. It involved 302 patients whose cancer had spread and who had already tried other treatment…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 04, 2026 00:21 UTC
-
Doctors track how COPD patients feel on new triple therapy
Disease control CompletedThis study observed how patients with moderate to severe COPD felt after starting a standard triple-inhaler medication (BGF MDI) in everyday Romanian clinics. It followed 10 patients for up to 6 months, primarily tracking changes in their self-reported health status and treatment…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
Daily pill tested to help adults breathe easier with asthma
Disease control CompletedThis study tested whether a daily pill called roflumilast could help improve lung function in adults with asthma. 450 participants with moderate asthma took either the medication or a placebo pill daily for 24 weeks. Researchers measured changes in breathing, asthma symptoms, and…
Phase: PHASE2, PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
New drug tested to keep Kids' stomach problems from coming back
Disease control CompletedThis study tested a medication called D961H in Japanese children aged 1-14. It aimed to see if the drug could safely prevent two types of stomach problems from returning: healed acid reflux and ulcers caused by long-term use of certain pain relievers. Children took the medication…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New pill shows promise in slowing advanced lung cancer
Disease control CompletedThis study tested a new daily pill, AZD9291, against standard daily pills for people with advanced lung cancer driven by a specific genetic change (EGFR mutation). It aimed to see if the new drug could better control the cancer and delay its progression. The trial involved 674 ad…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Spanish study tracks COPD patients on new triple inhaler
Disease control CompletedThis study looked back at the medical records of 718 adults in Spain with chronic obstructive pulmonary disease (COPD) who started using a triple-combination inhaler called Trixeo Aerosphere. The goal was to see how often patients experienced breathing flare-ups (exacerbations) a…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New pill aims to tame stubborn high blood pressure
Disease control CompletedThis study tested whether a new daily pill called baxdrostat could help lower blood pressure in adults whose high blood pressure wasn't controlled despite taking two or more standard medications. About 800 participants were randomly assigned to receive either baxdrostat or a plac…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New asthma inhaler aims for faster, longer relief
Disease control CompletedThis study tested if a new combination inhaler (PT027) works as well or better than a standard rescue inhaler (PT007) for adults with asthma. Researchers compared how quickly and for how long each inhaler improved breathing after a controlled breathing challenge. The goal was to …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Asthma Patients' real experiences tracked in global treatment study
Disease control CompletedThis study observed 291 patients with severe asthma who were prescribed benralizumab, a medication that reduces inflammation. Researchers tracked how patients' asthma control and quality of life changed over 56 weeks of treatment in real-world healthcare settings across multiple …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Scientists test new drug cocktails in fight against advanced cancers
Disease control CompletedThis study tested new combinations of experimental drugs for people with advanced cancers that had stopped responding to standard treatments. It first aimed to find safe doses in patients with various solid tumors. It then focused on people with advanced head and neck cancer to s…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
First human test of new Heart-Kidney drug completed
Disease control CompletedThis early-stage study tested the safety of an experimental oral drug called AZD4144 in people with both heart and kidney disease. Twenty-nine participants took either the drug or a placebo pill daily for 28 days. The main goal was to see if the drug was safe and to measure its e…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New inhaler aims to tame uncontrolled asthma Flare-Ups
Disease control CompletedThis study tested a new daily inhaler called AZD8630 for adults whose asthma is not well-controlled despite using standard inhalers. Over 500 participants used the inhaler or a placebo for 12 weeks to see if it could reduce the risk of asthma attacks and improve lung function. Th…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New asthma drug tested for Real-World cough relief
Disease control CompletedThis study followed 92 adults with severe asthma who were prescribed tezepelumab to see how well it controls asthma and reduces cough in real-world settings. Researchers measured asthma control and cough-related quality of life over 52 weeks to understand the drug's effectiveness…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New Double-Action drug tested for tough blood cancer
Disease control CompletedThis early-stage study tested a new drug called sabestomig (AZD7789) in adults and young adults whose Hodgkin lymphoma had returned or did not respond to at least two prior treatments. The main goals were to find a safe dose and see how the body processes the drug. The drug is de…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New inhaler combo tested for Tough-to-Control asthma
Disease control CompletedThis study tested if adding a second medicine (formoterol) to a common asthma steroid (budesonide) in one inhaler works better than the steroid alone for people whose asthma isn't well controlled. About 374 adults and teens used either the two-drug or one-drug inhaler twice daily…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New pill aims to tackle stubborn cholesterol
Disease control CompletedThis study tested whether a new daily pill called AZD0780 could lower 'bad' cholesterol (LDL-C) in people who already take statins. Over 400 adults with high cholesterol took different doses of the drug or a placebo for 12 weeks. Researchers measured cholesterol levels and checke…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Real-World check on Long-Term asthma drug safety
Disease control CompletedThis study aimed to monitor the long-term safety and effectiveness of the asthma medication FASENRA in real-world patients. It involved 653 people with severe asthma that was hard to control with other treatments. The main goal was to track any side effects and see how well the d…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested for scarred livers
Disease control CompletedThis study tested whether a combination of two drugs (zibotentan and dapagliflozin) is safe for people with liver cirrhosis. Researchers compared the combination against each drug alone and against a placebo in 73 patients across multiple countries. The main goal was to monitor s…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Drug safety under the microscope in korean asthma patients
Disease control CompletedThis study monitored the safety and effectiveness of FASENRA, a medication for severe asthma and a related condition called EGPA, in real-world Korean patients. Doctors observed 51 adults who were starting FASENRA treatment for the first time, following them for up to 48 weeks. T…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New weekly shot shows promise in fighting obesity
Disease control CompletedThis study tested whether a new weekly injection called AZD6234 helps people with obesity or overweight lose weight. About 262 adults received either the drug or a placebo (dummy injection) for 36 weeks. The main goal was to see if the drug led to better weight loss results compa…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
COPD patients tracked for a year on new triple inhaler
Disease control CompletedThis study followed 250 Italian adults with moderate-to-severe COPD for up to one year after they started using the Trixeo triple-therapy inhaler in routine care. Researchers tracked changes in breathing symptoms, quality of life, and healthcare visits to understand how the treat…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First human tests begin for potential Crohn's disease treatment
Disease control CompletedThis early-stage study tested a new experimental drug called AZD7798 in healthy volunteers and people with Crohn's disease. Researchers wanted to understand the drug's safety, side effects, and how the body processes it. The study involved 112 participants who received either the…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug shows promise in controlling debilitating lupus symptoms
Disease control CompletedThis study tested whether a drug called anifrolumab could better control active systemic lupus erythematosus (lupus) in Asian adults compared to a placebo. All 277 participants continued their standard lupus medications and received either the new drug or a placebo via IV every 4…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Doctors track COPD patients after switching to stronger inhaler
Disease control CompletedThis study observed 212 adults in Greece with moderate to severe COPD who were newly prescribed a triple-combination inhaler (Trixeo Aerosphere™) as part of their regular care. The goal was to see how patients felt and functioned over one year after switching to this stronger med…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
One pill or two? diabetes study tests which is easier for patients
Disease control CompletedThis study tested if a single pill combining two common diabetes medications (dapagliflozin and metformin) works as well as taking the two pills separately. It involved over 600 Chinese adults newly diagnosed with type 2 diabetes and lasted 24 weeks. The main goal was to see if t…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New weight loss pill shows promise in Mid-Stage trial
Disease control CompletedThis study tested whether a new daily pill called AZD5004 helps people lose weight compared to a placebo (dummy pill). It involved about 310 adults who were living with obesity or were overweight and had at least one related health condition, like high blood pressure. Participant…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Massive study tracks safety of new liver cancer treatments
Disease control CompletedThis study monitored the safety of two already-approved drugs, IMJUDO and IMFINZI, in real-world patients with advanced liver cancer that cannot be removed by surgery. It involved 1200 patients in Japan to collect safety information after the drugs were made available to doctors.…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New inhaler tested to help people breathe easier
Disease control CompletedThis study tested a new combination inhaler for asthma against a standard inhaler and an existing treatment. It involved 645 adults and teenagers whose asthma symptoms were not well controlled despite using daily medication. The goal was to see if the new inhaler improved lung fu…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Major lung cancer drug monitored in nearly 1,000 patients
Disease control CompletedThis study monitored 923 Korean patients with a specific type of lung cancer who were already prescribed the drug Tagrisso (osimertinib) by their doctors. The goal was to see how safe and effective the drug is in everyday, real-world use, not in a controlled trial. Researchers tr…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Drug aims to keep kidney patients out of the hospital
Disease control CompletedThis study tested whether continuing a potassium-lowering medication called SZC after hospital discharge helps people with chronic kidney disease better maintain safe potassium levels compared to standard care. It involved about 186 adults who were hospitalized for high potassium…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Drug safety check for breast cancer patients after surgery
Disease control CompletedThis study monitored the safety of LYNPARZA, a medication given after surgery to help prevent breast cancer from returning in high-risk patients. Researchers tracked 61 patients with specific genetic mutations to see how often they experienced bone marrow suppression, a known sid…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New heart pill aims to strengthen failing hearts
Disease control CompletedThis study tested a new daily pill called AZD5462 for people with stable chronic heart failure. Researchers wanted to see if different doses could improve how well the heart pumps and reduce symptoms, compared to a placebo. About 375 participants took the pill or a dummy pill for…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New inhaler tested to tame severe asthma attacks
Disease control CompletedThis study tested a new inhaled medication called AZD4604 for adults whose moderate-to-severe asthma was not well controlled by their usual high-dose inhalers. Over 300 participants used the drug or a placebo twice daily for 12 weeks. The main goal was to see if the new treatment…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New asthma inhaler tested against standard treatment
Disease control CompletedThis study compared two different inhaler treatments for adults with mild asthma over 12 weeks. Researchers tested whether a combination inhaler (AIRSUPRA) worked better than the standard albuterol inhaler at reducing airway inflammation and asthma symptoms. The study involved 10…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Drug maker tests if blood pressure pill affects Body's stress response
Disease control CompletedThis study tested whether an experimental drug called baxdrostat affects the body's ability to produce cortisol, a key stress hormone, in people whose high blood pressure isn't well controlled by current medications. Forty-eight participants took either baxdrostat or a placebo pi…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First human test of AstraZeneca's obesity pill
Disease control CompletedThis was a small, early-stage study to check if a new oral drug called AZD4144 is safe for people with obesity. Twenty-eight healthy adults with obesity took the drug or a placebo daily for up to 28 days. Researchers primarily looked for side effects and measured changes in blood…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New pill tested to tame severe asthma Flare-Ups
Disease control CompletedThis study tested whether a daily oral medication called atuliflapon could help control asthma and prevent worsening episodes in adults whose asthma was not well-managed with standard inhaler treatments. About 670 participants took either the study drug or a placebo pill for 12 w…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug tested to halt scarring in fatty liver disease
Disease control CompletedThis study tested whether a drug called cotadutide is safe and can help people with a type of fatty liver disease called NASH, which causes liver scarring. Fifty-four adults with confirmed liver scarring received either the drug or a placebo for about six months. The main goals w…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for advanced breast cancer? early trial tests novel drug combo
Disease control CompletedThis early-stage study tested the safety and how the body processes a new oral drug called AZD2014 when given alongside an existing breast cancer treatment, fulvestrant. It involved 99 adults with advanced, hormone-sensitive breast cancer that had spread. The main goal was to fin…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New asthma pill targets root inflammation in early trial
Disease control CompletedThis study tested whether a new oral medicine called AZD4604 could reduce inflammation in the airways of adults with moderate-to-severe asthma. For 4 weeks, 36 participants took either the drug or a placebo pill, and researchers measured changes in cells and genes from lung sampl…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New diabetes drug shows promise in blood sugar and weight control
Disease control CompletedThis study tested an experimental drug called AZD5004 in adults with type 2 diabetes. It aimed to see if the drug could help lower long-term blood sugar levels and reduce body weight compared to a placebo. The trial involved 406 participants and was designed to check the medicine…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug tested for stubborn high blood pressure that Won't budge
Disease control CompletedThis study tested whether a new drug called baxdrostat could help lower blood pressure in people with resistant hypertension—high blood pressure that stays high despite taking three or more medications. Over 200 participants were randomly assigned to receive either baxdrostat or …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New injection aims to ease strain on failing hearts and lungs
Disease control CompletedThis study tested whether a new injectable drug, AZD3427, could reduce high blood pressure in the lungs of people who also have heart failure. About 260 participants received either the drug or a placebo injection every two weeks for 24 weeks. The main goal was to see if the drug…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for lung cancer patients after standard treatment fails
Disease control CompletedThis study tested an experimental drug called AZD9291 for people in Asia Pacific with advanced non-small cell lung cancer. The participants had a specific genetic change (T790M mutation) and their cancer had gotten worse despite previous treatment with a common type of targeted t…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New injection aims to shrink stubborn nasal polyps, reduce need for surgery
Disease control CompletedThis large, completed Phase 3 trial tested whether a new injectable medication called tezepelumab could help adults with severe, long-term sinusitis and large nasal polyps. Over 400 participants received either tezepelumab or a placebo shot every four weeks for a year, while cont…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New asthma drug tested in diverse, Real-World patients
Disease control CompletedThis study looked at how well and how safely the injectable medication tezepelumab works for people with severe asthma in real-world settings. It included 287 adults and adolescents whose asthma was not well controlled despite using standard high-dose inhalers and other controlle…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Scientists test new cancer drug duo in hopeful early trial
Disease control CompletedThis early-stage study aimed to find a safe dose for a new two-drug combination (adavosertib and durvalumab) for patients with advanced solid tumors that had stopped responding to standard treatments. It involved 56 adult patients and tested different dosing schedules to see how …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug tested for stubborn Hormone-Linked high blood pressure
Disease control CompletedThis study tested an investigational drug called CIN-107 for adults with primary aldosteronism, a condition where the adrenal glands produce too much of a hormone, causing hard-to-control high blood pressure. The main goals were to see if the drug was safe and if it could effecti…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Asthma drug gets extended safety check
Disease control CompletedThis study followed asthma patients for 28 weeks to check the long-term safety of roflumilast, a daily pill. It continued from a previous 24-week study, tracking 150 adults who had already completed that trial. The main goal was to see if the medication remained safe and effectiv…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Israeli study reveals how well a severe asthma drug works in real patients
Disease control CompletedThis study looked back at medical records to see how well the drug benralizumab worked for 197 adults with severe asthma in Israel. Researchers tracked patients for up to five years to measure how many asthma flare-ups they experienced before and after starting treatment. The goa…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
First human test of potential new asthma treatment
Disease control CompletedThis early-stage study tested the safety and how the body processes a new inhaled drug called AZD8630 in adults with moderate-to-severe asthma. Twenty-four participants who were already using standard asthma inhalers took either the new drug or a placebo once daily for two weeks.…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New heart drug shows promise in lowering blood pressure
Disease control CompletedThis study tested whether an experimental drug called AZD0780 could lower blood pressure in people with heart disease or high risk for it. Researchers measured blood pressure changes over 24 hours in 202 adults who already had high cholesterol. Participants took either the drug o…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New cholesterol pill tested in early safety study
Disease control CompletedThis early-stage study tested a new experimental drug called AZD0780 when added to existing cholesterol-lowering medications. Researchers enrolled 81 healthy adults with high 'bad' LDL cholesterol to check how the body processes the drug, its safety, and its effect on cholesterol…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Drug safety check: tracking side effects in new leukemia patients
Disease control CompletedThis study monitored the safety of Calquence (acalabrutinib) in real-world patients with previously untreated chronic lymphocytic leukemia. It tracked how often side effects like infections and low blood counts occurred after the drug was approved for this use. The goal was to un…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Doctors track COPD patients on common triple therapy
Disease control CompletedThis study observed patients with moderate-to-severe COPD who were newly prescribed the inhaled medication BREZTRI in routine Russian clinics. Researchers tracked their symptoms, breathing ability, and treatment satisfaction over 24 weeks to see how they fared in real-world use. …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Drug safety under the microscope for Tough-to-Treat blood cancer
Disease control CompletedThis study monitored the safety of the drug Calquence (acalabrutinib) in a real-world setting after it was approved for use. It involved 104 patients whose chronic lymphocytic leukemia had returned or did not respond to prior treatment. The main goal was to track the frequency an…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New asthma drug shows Real-World promise for severe cases
Disease control CompletedThis study followed 513 people with severe, hard-to-control asthma for one year after they started taking tezepelumab, a prescription medication. The goal was to see how well the drug worked in everyday life, outside of a controlled clinical trial, by tracking asthma symptoms, br…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Targeted genetic therapy tested for common liver disease
Disease control CompletedThis study tested an investigational injection called AZD2693 to see if it could treat NASH, a type of fatty liver disease that causes scarring. It specifically enrolled 220 adults with NASH and liver scarring who carry a certain gene (PNPLA3 148M) that increases their risk. The …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Major trial tests promising new drug for common adult leukemia
Disease control CompletedThis large, global study aimed to understand the safety and effectiveness of the drug acalabrutinib for adults with chronic lymphocytic leukemia (CLL). It included over 550 people, including those newly diagnosed, those whose cancer returned, and those who had taken a similar dru…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Drug safety under scrutiny for advanced pancreatic cancer patients
Disease control CompletedThis study monitored the safety of LYNPARZA, a maintenance drug, in 130 patients with a specific type of advanced pancreatic cancer (BRCA-mutated) who had already finished platinum-based chemotherapy. The goal was to track and understand the side effects that occurred in real-wor…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New asthma inhaler propellant tested for safety
Disease control CompletedThis study tested whether a new propellant (HFO) in asthma inhalers causes breathing problems compared to the current propellant (HFA). Researchers enrolled 52 adults with well-controlled asthma who tried both propellants in a single dose. They measured lung function immediately …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Cancer Drug's Real-World performance tracked in major korean study
Disease control CompletedThis study monitored how well the cancer drug durvalumab (Imfinzi) worked and how safe it was for patients in everyday medical practice in Korea. It included 712 people with lung cancer or biliary tract cancer who were eligible to receive the drug as per its approved label. The m…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
Post-Approval watch: tracking side effects of new cancer combo
Disease control CompletedThis study monitored the safety of a drug called IMFINZI when used with standard chemotherapy in 236 patients with advanced bile duct cancer that cannot be removed by surgery. It was conducted in Japan after the treatment was approved, to better understand the real-world side eff…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
Breakthrough drug helps severe asthma patients ditch harmful steroids
Disease control CompletedThis study tested whether a drug called tezepelumab, given as a shot, could help adults with severe asthma safely reduce or stop their daily oral steroid pills. It involved 305 participants who were already taking high doses of inhaled medicine plus daily steroid pills. The main …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 11, 2026 14:52 UTC
-
Targeted therapy tested for tough prostate cancer cases
Disease control CompletedThis study tested whether a targeted drug called olaparib works better than standard hormone treatments for Chinese men with advanced prostate cancer that has spread and stopped responding to other hormone therapies. The men in the study all had specific genetic changes (BRCA1/2 …
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC
-
Simple breath test could help doctors target cough treatment
Diagnosis CompletedThis study aimed to find a specific level on a simple breath test (FeNO) that could predict whether adults with a chronic dry cough would respond to a standard asthma inhaler treatment. About 1000 participants in China with a cough lasting at least 8 weeks used the inhaler for 8 …
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Mar 31, 2026 12:11 UTC
-
New asthma inhaler put to test against common rescue medication
Symptom relief CompletedThis study tested a new asthma inhaler called PT007 against a placebo (dummy treatment) and the commonly used rescue inhaler Ventolin. Researchers enrolled 118 adults with asthma to see how well PT007 opens airways and how safe it is. Each participant tried all three treatments i…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Symptom relief
Last updated Apr 03, 2026 14:41 UTC
-
New inhalers tested to help COPD patients breathe easier during exercise
Symptom relief CompletedThis completed Phase 3 study tested two combination inhalers against a placebo inhaler in 171 people with moderate-to-severe COPD who get short of breath during exercise. The goal was to see if the inhalers could help patients breathe better and exercise longer by reducing lung i…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Symptom relief
Last updated Mar 23, 2026 15:18 UTC
-
Doctors look back: how did a new asthma drug perform in real patients?
Knowledge-focused CompletedThis study looked back at the medical records of 420 patients in Spain who received the asthma medication tezepelumab after it became available to the public. The goal was to understand the real-world characteristics of these patients and see how the treatment affected their asth…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 04, 2026 00:26 UTC
-
First human test for liver disease drug begins
Knowledge-focused CompletedThis was the first study in people for a potential new drug called AZD4076, which is being developed for a serious liver disease called NASH. The main goal was to check if single, increasing doses of the drug were safe and well-tolerated in 40 healthy male volunteers. Researchers…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 04, 2026 00:21 UTC
-
Massive screening reveals hidden kidney disease across brazil
Knowledge-focused CompletedThis study aimed to find out how many Brazilian adults with risk factors actually have chronic kidney disease. Researchers used a quick finger-prick test at local clinics to screen over 8,400 people across the country. People with abnormal results were referred for more detailed …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 04, 2026 00:21 UTC
-
Scientists map genetic blueprint of lung cancer resistance
Knowledge-focused CompletedThis study aimed to understand why advanced lung cancer stops responding to the first-line treatment osimertinib. Researchers analyzed genetic changes in tumor tissue and blood samples from 182 patients whose cancer had progressed despite treatment. The goal was to identify patte…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 04, 2026 00:20 UTC
-
Major cancer study maps treatment landscape for thousands
Knowledge-focused CompletedThis study looked back at the medical records of 1,669 Russian patients with a specific type of advanced breast cancer called 'HER2-low.' Its main goal was to understand how common this cancer subtype is and to see what treatments doctors were using in real-world hospitals. Resea…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:49 UTC
-
First human test: how kidneys handle experimental drug
Knowledge-focused CompletedThis early-stage study tested how the experimental drug AZD4144 is processed by the body in people with different levels of kidney function. Researchers gave a single dose to 41 participants, including healthy volunteers and people with mild to severe kidney impairment or end-sta…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test new Drug's safety with common pills
Knowledge-focused CompletedThis early-stage study tested how an experimental drug, AZD5004, interacts with several common medications, including cholesterol drugs (like atorvastatin) and a diabetes drug (repaglinide). It involved 49 healthy adult volunteers to see if taking AZD5004 changes how the body pro…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC
-
First human test for new gut infection drug
Knowledge-focused CompletedThis early-stage study aimed to check the safety and see how the body processes a single dose of a new drug called AZD5148. It involved 16 healthy Japanese adults who received the drug either as a shot in the muscle or through an IV. The main goal was to monitor for any side effe…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC
-
Drug safety watch: tracking side effects of COVID-19 treatment in japan
Knowledge-focused CompletedThis study monitored the safety of Evusheld, a drug used to treat and prevent symptomatic COVID-19, in real-world Japanese patients. Researchers tracked side effects in 366 people who received the drug as part of their regular medical care after it was approved for use. The goal …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC
-
Scientists track hidden heart failure risk in diabetics
Knowledge-focused CompletedThis study aimed to understand how common undiagnosed heart failure is in people with type 2 diabetes who are at high risk for heart problems. Researchers followed 245 patients in Greece for two years to see who developed symptoms and to identify early warning signs. The goal was…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC
-
Doctors review records to see how asthma drug performs in real life
Knowledge-focused CompletedThis study looked back at the medical records of 352 adults in the UK with severe asthma who were treated with the drug tezepelumab. The goal was to understand how the drug works for patients in real-world clinics, not just in controlled trials. Researchers collected data on asth…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC
-
Can better doctor training lead to better asthma control?
Knowledge-focused CompletedThis study tested whether a training program for lung doctors and nurses could improve how they follow asthma treatment guidelines. About 1500 patients with asthma across China were followed for 48 weeks to see if the doctors' training led to better treatment choices and improved…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:41 UTC
-
Drug maker tests new compound in healthy volunteers
Knowledge-focused CompletedThis early-stage study aimed to check the safety and see how the body processes a single dose of an experimental drug called AZD5148. It involved 84 healthy adult volunteers who received the drug or a placebo via injection. The main goal was to monitor for side effects and measur…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:41 UTC
-
Drug maker tests new compound in healthy people
Knowledge-focused CompletedThis early-stage study tested a new compound called AZD1163 in healthy volunteers to see if it's safe and how the body processes it. Researchers gave different doses to 108 participants, either through an IV or injection, and monitored them for side effects. The main goal was to …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:41 UTC
-
Mapping the journey: how latin america detects lung problems
Knowledge-focused CompletedThis study observed how doctors across Latin America find, diagnose, and decide on treatment for lung nodules (small spots in the lungs). Researchers tracked over 500 patients to understand the steps, timing, and resources used from when a nodule is first seen on a scan to when a…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:58 UTC
-
Scientists test new drug in people with liver damage
Knowledge-focused CompletedThis study tested how a single injection of an experimental drug (AZD2693) is processed by the body in people with different levels of liver problems. Researchers compared 24 people with mild, moderate, or severe liver impairment to 8-12 people with normal liver function. The mai…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:57 UTC
-
Researchers map Brazil's liver cancer landscape
Knowledge-focused CompletedThis study looked back at medical records of 300 Brazilian liver cancer patients treated between 2017 and 2022. Researchers analyzed how the cancer was diagnosed, what treatments patients received, and how they responded over time. The goal was to better understand liver cancer p…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:57 UTC
-
Doctors track how a drug manages dangerous potassium levels
Knowledge-focused CompletedThis study aimed to understand how doctors in Greece treat patients with high potassium levels (hyperkalaemia) who also have kidney disease or heart failure. Researchers observed the real-world use of a medication called sodium zirconium cyclosilicate in about 120 patients over s…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC
-
Study tracks Real-World use of advanced breast cancer drug
Knowledge-focused CompletedThis study observed how patients with advanced HER2-positive or HER2-low breast cancer used the drug trastuzumab deruxtecan (T-DXd) in routine Canadian clinics. Researchers tracked 22 patients to see how often treatment was stopped early or doses were changed, and how long patien…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC
-
Scientists track diarrhea samples to improve future c. diff testing
Knowledge-focused CompletedThis study aimed to figure out the best practical methods for collecting, shipping, and testing stool and blood samples from adults with active C. difficile (C. diff) infections. It observed participants to see how well they could complete sample collection and questionnaires, an…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC
-
Doctors review Real-World results for severe asthma drug
Knowledge-focused CompletedThis study looked back at the medical records of 74 adults in Portugal with severe asthma who were treated with the drug benralizumab. The goal was to understand what types of patients received the drug, how it was used in real hospitals, and what happened to their asthma symptom…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC
-
First human tests: scientists check safety of new inhaled drug
Knowledge-focused CompletedThis was an early-stage study to check if a new inhaled drug called AZD4604 is safe and how the body processes it. It involved 56 healthy Japanese and Chinese volunteers who received either the drug or a placebo. The main goal was to see if the drug caused any side effects and to…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Drug safety under the microscope in major kidney disease study
Knowledge-focused CompletedThis study aimed to monitor the safety of the drug Forxiga (dapagliflozin) when used by over 1,000 patients with chronic kidney disease in real-world medical settings. It specifically looked to identify any unexpected side effects and understand what factors might influence safet…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Researchers examine how treatment setbacks affect cancer care duration
Knowledge-focused CompletedThis study looked back at the medical records of 730 patients in Japan with advanced bile duct cancer who received standard drug treatment. Researchers wanted to understand if serious bile duct complications that required hospital stays affected how long patients could continue t…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Diabetes drug safety tracked in 1,000+ patients
Knowledge-focused CompletedThis study monitored 1,001 adults with type 2 diabetes in Vietnam who were newly prescribed Forxiga (dapagliflozin). Researchers followed patients for 24 weeks to track any side effects that occurred during routine medical care. The goal was to understand the real-world safety pr…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Cancer drug side effects closely tracked in over 1,000 patients
Knowledge-focused CompletedThis study observed how Chinese patients with ovarian or prostate cancer tolerated the cancer drug olaparib during regular medical care. Researchers followed 1,018 patients for 6-12 months to track side effects and treatment patterns. The goal was to understand the drug's safety …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Scientists test drug mix safety in healthy women
Knowledge-focused CompletedThis early-stage study tested how an experimental breast cancer drug called camizestrant interacts with two common medications: midazolam (a sedative) and carbamazepine (an anti-seizure drug). Researchers enrolled 40 healthy postmenopausal women to measure how these drugs affect …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Major study maps the gaps in lupus diagnosis and treatment
Knowledge-focused CompletedThis study aimed to understand the challenges and unmet needs in caring for people with systemic lupus erythematosus (SLE). Researchers analyzed existing health data and gathered opinions from specialist doctors to identify gaps in diagnosis, treatment, and patient support. The g…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:18 UTC
-
Looking back: how did a cancer drug perform in real patients?
Knowledge-focused CompletedThis study looked back at the medical records of 342 women in Europe with advanced ovarian cancer linked to a BRCA gene mutation. The goal was to see how well the drug olaparib worked and how it was used in real-world settings after initial chemotherapy. Researchers collected dat…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
First safety test for new drug in people with kidney disease
Knowledge-focused CompletedThis early-stage study tested how a single dose of an experimental drug, AZD6234, is processed by the body in people with different levels of kidney problems. Researchers compared 24 people with mild to severe kidney impairment, including some on dialysis, to healthy volunteers. …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Massive 3-Year study maps the hidden struggles of severe asthma patients
Knowledge-focused CompletedThis study aimed to understand how adults with severe, hard-to-control asthma are treated and how they fare in everyday life. Researchers followed over 1,500 patients across the US for at least three years, collecting data through regular online surveys and medical records. The g…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
First human test: how does a damaged liver handle new medicine?
Knowledge-focused CompletedThis early-stage study tested how a new drug called AZD5004 is processed by people with different levels of liver damage compared to people with healthy livers. Researchers gave a single dose to 33 adults with mild, moderate, or severe liver impairment, plus a matched healthy gro…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
First Real-World glimpse at asthma drug before market launch
Knowledge-focused CompletedThis study looked back at medical records to see how 33 patients with severe, hard-to-control asthma responded to the drug tezepelumab in real Spanish clinics. The goal was to gather the first information on how the drug worked outside of formal clinical trials, specifically for …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC
-
Scientists test new drug's safety in people with liver issues
Knowledge-focused CompletedThis study looked at how a new drug called AZD2389 is processed by the body in people with different levels of liver problems compared to people with normal liver function. It involved 35 participants who received a single dose of the drug. The main goal was to understand how liv…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Dutch study scrutinizes outcomes for emergency bleeding treatment
Knowledge-focused CompletedThis study looked back at the medical records of 217 patients in the Netherlands who were hospitalized for severe bleeding while taking certain blood thinners. All patients received a specific drug (andexanet alfa) designed to reverse the blood thinner's effect. The goal was to u…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
First human test for mystery drug AZD2389
Knowledge-focused CompletedThis was the first study in people for a new drug called AZD2389. Its main goal was to check if the drug is safe and to see how the body absorbs and processes it. The study involved 120 healthy volunteers, including people of Japanese and Chinese descent, who received either the …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Scientists test drug mix safety in healthy volunteers
Knowledge-focused CompletedThis study tested how an experimental cancer drug called capivasertib might change the way the body processes a common cholesterol-lowering drug, rosuvastatin. Twenty healthy volunteers took both drugs separately and together so researchers could measure the levels in their blood…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC
-
Researchers track how patients fare on new heart pill
Knowledge-focused CompletedThis study observed 257 patients in Greece who were newly prescribed dapagliflozin for heart failure. The goal was to understand how patients use the medication in real life and how it affects their quality of life. Researchers tracked whether patients continued taking the drug a…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC
-
Researchers dig through medical records to map elusive breast cancer type
Knowledge-focused CompletedThis study looked back at medical records to understand how common a specific subtype of breast cancer called 'HER2-low' is in the Gulf region. Researchers reviewed records of 517 women with advanced breast cancer to count cases and describe patient experiences. The goal is to ga…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC
-
Drug watch: tracking a rare disease treatment in real patients
Knowledge-focused CompletedThis study observed 11 adult patients in Korea who were already taking or starting Soliris for a rare autoimmune disorder called Neuromyelitis Optica Spectrum Disorder (NMOSD). Its main purpose was to collect real-world information on the drug's safety and how well it prevents di…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Massive study reveals how spanish doctors treat kidney disease
Knowledge-focused CompletedThis study looked back at the medical records of over 91,000 Spanish adults with chronic kidney disease to understand how doctors manage this condition in everyday practice. Researchers analyzed what treatments patients received, how often they started or stopped medications, and…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Drug maker tests different injection pens in healthy volunteers
Knowledge-focused CompletedThis study tested whether two different injection devices—a prefilled syringe and an autoinjector pen—deliver the same amount of an experimental drug called tozorakimab into the body. Researchers gave a single injection to 254 healthy volunteers and tracked the drug levels in the…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Scientists check if common pill alters cancer drug
Knowledge-focused CompletedThis study aimed to understand how a common antifungal drug (itraconazole) affects the blood levels of a lung cancer drug (AZD9291, now known as osimertinib). It involved 39 adults with a specific type of advanced lung cancer that had worsened after previous treatment. The main g…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC
-
Early safety check: how a potential liver drug moves through different bodies
Knowledge-focused CompletedThis early-stage study aimed to understand how the experimental drug zibotentan is absorbed, distributed, and eliminated by the body in healthy volunteers. It involved 30 healthy Japanese and non-Asian participants who each received four different single doses of the drug over se…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC
-
Sticky sensor tracks heart recovery from home
Knowledge-focused CompletedThis study tested a wearable heart monitor patch to see if it could reliably track recovery in patients recently hospitalized for sudden, severe heart failure. About 54 participants wore the patch at home for a few days right after leaving the hospital and again 6-8 weeks later. …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Major study Re-Examines breast cancer types to guide future treatments
Knowledge-focused CompletedThis study looked back at the medical records of over 1,100 patients with advanced breast cancer in Asia and Latin America. The goal was to understand how many patients actually have a specific subtype called 'HER2-low' by re-checking old tissue samples. Researchers also wanted t…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
First human tests: drug maker checks safety of new pill in asian volunteers
Knowledge-focused CompletedThis was an early-stage study to check the safety and see how the body processes a new oral drug called AZD6793. It involved 39 healthy Japanese and Chinese volunteers who received either the drug or a placebo. The main goal was to understand the drug's side effects and how it mo…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:41 UTC
-
Drug interaction test: experimental heart drug meets diabetes pill
Knowledge-focused CompletedThis study tested how an experimental heart medication called AZD0780 affects the way the body processes metformin, a common diabetes drug. Researchers gave both drugs to 14 healthy volunteers to measure how they interact in the body. The goal was to understand if taking these me…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC
-
Massive data dive: 361,000 brazilian COVID hospital records analyzed
Knowledge-focused CompletedThis study looked back at the health records of over 361,000 adults hospitalized with COVID-19 in Brazil between 2021 and 2023. Researchers used a national public health database to describe who was hospitalized, their outcomes, and the impact of vaccination. The goal was to unde…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
First human test: new arthritis Drug's safety check
Knowledge-focused CompletedThis early study tested a new potential rheumatoid arthritis drug called AZD6912 in 40 healthy volunteers. Researchers gave single injections at increasing doses to check for side effects and see how the body processes the drug. The main goal was to determine if the drug is safe …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
Massive study maps the Real-World journey of blood thinner bleeds
Knowledge-focused CompletedThis study aimed to better understand what happens to patients who experience a major bleeding event while taking a common type of blood thinner (Factor Xa inhibitor). Researchers observed over 2,200 hospitalized patients to learn about their characteristics, the medical care the…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
Cancer patients share their treatment stories
Knowledge-focused CompletedThis study aimed to learn directly from patients about their experiences taking a specific drug combination (capivasertib + fulvestrant) for advanced breast cancer. Researchers interviewed 48 people who had taken the treatment to understand their attitudes, dosing experiences, an…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:07 UTC
-
Doctors review Real-World results for key lung cancer drug
Knowledge-focused CompletedThis study looked back at the medical records of 350 Australian patients with advanced lung cancer who had a specific genetic change (EGFR mutation). Researchers analyzed how long patients stayed on a targeted drug called osimertinib, and how it affected their survival, when it w…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
Researchers unfold hidden cancer subtype in egypt
Knowledge-focused CompletedThis study looked back at the medical records of 405 Egyptian patients with advanced breast cancer. Its main goal was to find out how many of these patients had a specific subtype called 'HER2-low,' which is a newer way to classify the disease. The results will help doctors under…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:29 UTC
-
First human test for mystery drug AZD8965
Knowledge-focused CompletedThis was the first study in humans for a new drug called AZD8965. Its main goal was to check if the drug is safe and to see how the body absorbs and processes it. The study involved 147 healthy volunteers, including specific groups of Japanese and Chinese participants. Researcher…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:18 UTC
-
Landmark study maps rare blood disease in china
Knowledge-focused CompletedThis study aimed to better understand a rare and serious blood disease called Paroxysmal Nocturnal Hemoglobinuria (PNH) in China. Researchers observed 724 patients with PNH to learn about their disease characteristics, symptoms, and how different treatments, including a newer dru…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:16 UTC
-
Scientists track COPD's daily ups and downs
Knowledge-focused CompletedThis study aimed to better understand Chronic Obstructive Pulmonary Disease (COPD) by closely tracking patients over 12 weeks. Researchers observed how daily symptoms, lung function, and markers of inflammation in the body changed and related to each other. The information gather…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC
-
Inhaler propellant test: does new formula clear lungs better?
Knowledge-focused CompletedThis study tested whether a new, more environmentally friendly inhaler propellant (HFO) works as well as the current standard (HFA) at helping clear mucus from healthy lungs. Thirty-five healthy, non-smoking adults used both types of inhalers for one week each. Researchers used a…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:56 UTC
-
First test: how kidneys handle new drug
Knowledge-focused CompletedThis early study aimed to understand how a single dose of an experimental drug, AZD5462, is processed by the body in people with moderate to severe kidney problems. It compared 16 participants with reduced kidney function to healthy volunteers to check for safety and see if the d…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC
-
Retrospective study sheds light on deadly brain bleed complications
Knowledge-focused CompletedThis study looked back at the medical records of 123 adults who were hospitalized with a brain bleed while taking a common type of blood thinner (called a Factor Xa inhibitor). The goal was to understand what these patients were like, how they were treated, and what happened to t…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 17, 2026 12:55 UTC
-
Cancer registry tracks patient experience with Cutting-Edge drugs
Knowledge-focused CompletedThis study created a patient registry to observe how newer, targeted cancer drugs work in everyday practice for people with mantle cell lymphoma. It followed 227 patients who had recently started one of these newer treatments to track their treatment patterns, how well the drugs …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:26 UTC
-
Landmark survey reveals steroid reliance for Egypt's severe asthma patients
Knowledge-focused CompletedThis study aimed to gather information, not test a treatment. Researchers surveyed 201 adults with severe asthma across Egypt to find out how many rely on oral steroid pills to manage their condition. They also collected data on patients' specific disease features and how well th…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:26 UTC
-
Doctors track Real-Life results of kidney drug in eastern europe
Knowledge-focused CompletedThis study observed how doctors use the medication dapagliflozin to treat chronic kidney disease in everyday practice. It followed over 1,000 patients across seven Eastern European countries for up to a year after they started the drug. The goal was to understand which patients r…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:24 UTC
-
Massive russian study maps the hidden burden of severe lupus
Knowledge-focused CompletedThis study aimed to gather real-world information about patients in Russia living with moderate to severe systemic lupus erythematosus (SLE), a complex autoimmune disease. Researchers collected existing medical records and followed about 600 patients for over a year to understand…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 12, 2026 13:52 UTC
-
Scientists test how cancer drug mixes with cholesterol pill
Knowledge-focused CompletedThis study tested how a new lung cancer drug (AZD9291) affects the body's processing of a common cholesterol medication (simvastatin). Researchers enrolled 52 patients with advanced lung cancer that had stopped responding to standard treatments. The goal was to understand potenti…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 12, 2026 13:51 UTC
-
Scientists test new Drug's safety with common pills
Knowledge-focused CompletedThis early-stage study tested how a new drug called AZD5004 interacts with other medications in healthy volunteers. In one part, researchers checked if a common antifungal drug (itraconazole) changed how AZD5004 works in the body. In another part, they tested if AZD5004 changed h…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 10, 2026 12:53 UTC
-
First human tests for potential lung disease treatment
Knowledge-focused CompletedThis early-stage study aimed to check the safety and see how the body processes a new drug called AZD6793. It involved healthy volunteers and a small group of people with moderate-to-severe COPD, a chronic lung disease. The main goal was to understand side effects and how the dru…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 09, 2026 14:24 UTC
-
First look: new asthma inhaler tested in teens
Knowledge-focused CompletedThis study tested a single dose of a new inhaled asthma medicine called AZD8630 in 10 teenagers with asthma. The main goal was to see how the drug moves through the body and to check for any side effects. Researchers also tested the inhaler device used to deliver the medicine.
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 09, 2026 14:23 UTC
-
Brazilian cancer care under the microscope: how 204 patients were treated
Knowledge-focused CompletedThis study looked back at medical records to understand how doctors in Brazil treat advanced breast cancer that has spread or cannot be surgically removed. Researchers analyzed data from 204 adult patients who had already received a specific type of targeted therapy. The goal was…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 03, 2026 14:07 UTC
-
Does quick action after a COPD crisis save lives?
Knowledge-focused CompletedThis study looked back at existing health records to understand what happens to people with COPD after they have a severe flare-up requiring hospitalization. Researchers analyzed data from over 3,500 patients who started a specific inhaler medication (BGF) to see if starting it p…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 02, 2026 15:27 UTC